Neurocrine Biosciences Inc (NBIX)
125.00
+1.71
(+1.39%)
USD |
NASDAQ |
Nov 21, 16:00
123.15
-1.85
(-1.48%)
After-Hours: 20:00
Neurocrine Biosciences Net Income (Quarterly): 129.80M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 129.80M |
| June 30, 2024 | 65.00M |
| March 31, 2024 | 43.40M |
| December 31, 2023 | 147.70M |
| September 30, 2023 | 83.10M |
| June 30, 2023 | 95.50M |
| March 31, 2023 | -76.60M |
| December 31, 2022 | 89.00M |
| September 30, 2022 | 68.50M |
| June 30, 2022 | -16.90M |
| March 31, 2022 | 13.90M |
| December 31, 2021 | -7.30M |
| September 30, 2021 | 22.50M |
| June 30, 2021 | 42.30M |
| March 31, 2021 | 32.10M |
| December 31, 2020 | 347.90M |
| September 30, 2020 | -57.60M |
| June 30, 2020 | 79.60M |
| March 31, 2020 | 37.40M |
| December 31, 2019 | 34.00M |
| September 30, 2019 | 53.80M |
| June 30, 2019 | 51.30M |
| March 31, 2019 | -102.10M |
| December 31, 2018 | 18.07M |
| September 30, 2018 | 50.76M |
| Date | Value |
|---|---|
| June 30, 2018 | -5.913M |
| March 31, 2018 | -41.82M |
| December 31, 2017 | 6.894M |
| September 30, 2017 | -11.12M |
| June 30, 2017 | -59.98M |
| March 31, 2017 | -78.33M |
| December 31, 2016 | -44.66M |
| September 30, 2016 | -36.89M |
| June 30, 2016 | -40.28M |
| March 31, 2016 | -19.26M |
| December 31, 2015 | -29.32M |
| September 30, 2015 | -34.44M |
| June 30, 2015 | -23.99M |
| March 31, 2015 | -1.192M |
| December 31, 2014 | -19.44M |
| September 30, 2014 | -15.88M |
| June 30, 2014 | -13.38M |
| March 31, 2014 | -11.84M |
| December 31, 2013 | -10.64M |
| September 30, 2013 | -11.13M |
| June 30, 2013 | -12.24M |
| March 31, 2013 | -12.08M |
| December 31, 2012 | 9.49M |
| September 30, 2012 | -3.078M |
| June 30, 2012 | -0.501M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-76.60M
Minimum
Mar 2023
347.90M
Maximum
Dec 2020
58.66M
Average
42.85M
Median
Net Income (Quarterly) Benchmarks
| Repligen Corp | -0.654M |
| West Pharmaceutical Services Inc | 136.00M |
| Bruker Corp | 40.90M |
| The Cooper Companies Inc | 104.70M |
| Integra Lifesciences Holdings Corp | -10.70M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 622.10M |
| Total Expenses (Quarterly) | 437.30M |
| EPS Diluted (Quarterly) | 1.24 |
| Enterprise Value | 11.43B |
| Gross Profit Margin (Quarterly) | 98.71% |
| Profit Margin (Quarterly) | 20.86% |
| Earnings Yield | 2.98% |
| Operating Earnings Yield | 4.55% |
| Normalized Earnings Yield | 2.531 |